58347-49-2

Usage

Uses

Used in Medicinal Chemistry:
7-Chloropyrazolo[1,5-a]pyrimidine is utilized as a pharmaceutical intermediate for the development of new drugs. Its unique structure and chemical properties make it a promising candidate for the synthesis of compounds with potential anticancer and antiviral activities.
Used in Anticancer Applications:
In the field of oncology, 7-Chloropyrazolo[1,5-a]pyrimidine is employed as an anticancer agent. It has demonstrated the ability to inhibit the growth and proliferation of cancer cells, making it a valuable component in the development of novel therapeutic agents for the treatment of various types of cancer.
Used in Antiviral Applications:
7-Chloropyrazolo[1,5-a]pyrimidine also shows potential as an antiviral agent. Its ability to interfere with viral replication and infection processes makes it a useful compound in the development of new antiviral drugs to combat various viral diseases.
Used in Organic Synthesis:
As a versatile intermediate in organic synthesis, 7-Chloropyrazolo[1,5-a]pyrimidine can undergo various chemical reactions to produce a wide range of derivatives with different properties and applications. This makes it a valuable building block for the synthesis of complex organic molecules and compounds with potential uses in various industries, including pharmaceuticals, agrochemicals, and materials science.

InChI:InChI=1/C6H4ClN3/c7-5-1-3-8-6-2-4-9-10(5)6/h1-4H

Upstream product

• 29274-23-5 4,7-dihydropyrazolo<1,5-a>pyrimidin-7-one 
• 197367-75-2 7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxylic acid 
• 29274-18-8 ethyl 7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-6-carboxylate 
• 57489-79-9 4H-pyrazolo[1,5-a]pyrimidin-7-one 

Downstream Products

• 137739-28-7 7-(3,5-di-t-butyl-4-hydroxyphenyl)aminopyrazolo[1,5-a]pyrimidine 
• 877173-84-7 3-bromo-7-chloropyrazolo[1,5-a]pyrimidine 
• 1404086-53-8 (S)-N-(1-(5-Methoxy-3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)ethyl)pyrazolo[1,5-a]pyrimidin-7-amine 

Relevant academic research and scientific papers

Selective Halogenation of Pyridines Using Designed Phosphine Reagents

Halopyridines are key building blocks for synthesizing pharmaceuticals, agrochemicals, and ligands for metal complexes, but strategies to selectively halogenate pyridine C-H precursors are lacking. We designed a set of heterocyclic phosphines that are installed at the 4-position of pyridines as phosphonium salts and then displaced with halide nucleophiles. A broad range of unactivated pyridines can be halogenated, and the method is viable for late-stage halogenation of complex pharmaceuticals. Computational studies indicate that C-halogen bond formation occurs via an SNAr pathway, and phosphine elimination is the rate-determining step. Steric interactions during C-P bond cleavage account for differences in reactivity between 2- and 3-substituted pyridines.

Novel Hinge-Binding Motifs for Janus Kinase 3 Inhibitors: A Comprehensive Structure-Activity Relationship Study on Tofacitinib Bioisosteres

The Janus kinases (JAKs) are a family of cytosolic tyrosine kinases crucially involved in cytokine signaling. JAKs have been demonstrated to be valid targets in the treatment of inflammatory and myeloproliferative disorders, and two inhibitors, tofacitinib and ruxolitinib, recently received their marketing authorization. Despite this success, selectivity within the JAK family remains a major issue. Both approved compounds share a common 7H-pyrrolo[2,3-d]pyrimidine hinge binding motif, and little is known about modifications tolerated at this heterocyclic core. In the current study, a library of tofacitinib bioisosteres was prepared and tested against JAK3. The compounds possessed the tofacitinib piperidinyl side chain, whereas the hinge binding motif was replaced by a variety of heterocycles mimicking its pharmacophore. In view of the promising expectations obtained from molecular modeling, most of the compounds proved to be poorly active. However, strategies for restoring activity within this series of novel chemotypes were discovered and crucial structure-activity relationships were deduced. The compounds presented may serve as starting point for developing novel JAK inhibitors and as a valuable training set for in silico models.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

Imidazopyridine derivatives as PI3K inhibitors

New imidazopyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks)

IMIDAZOPYRIDINE DERIVATIVES AS PI3K INHIBITORS

New imidazopyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks).

PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS

New pyrrolotriazinone derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks).

PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The present invention relates to certain pyrazolo[1,5-a]pyrimidine compounds, to processes for their preparation, compositions comprising them and methods of using them. The compounds are useful in the treatment of cancer. Novel screening methods are also

Pyrazolopyrimidines as protein kinase inhibitors

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a] pyrimidine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions.